Sublobectomy Versus Lobectomy for Stage I Non-small Cell Lung Cancer in the Elderly
Overview
Affiliations
Objective: The aim of our study was to compare the operative characteristics and long term survival for elderly patients with stage I non-small cell lung cancer (NSCLC) who underwent sublobectomy versus lobectomy.
Methods: We identified 245 consecutive elderly patients (≥65y) with pathologic stage I NSCLC who underwent lobectomy or sublobectomy at our institution between 2006 and 2012, and assessed the operative characteristics, recurrence, and survival differences between these approaches.
Results: A total of 39 patients underwent sublobectomy and 206 patients had lobectomy. There were significantly more COPD (p = 0.046) and low percent of predicted FEV1 (p = 0.034) in sublobectomy patients compared to the lobectomy group. Sublobectomy patients had significantly shorter operating time (p = 0.001), less blood loss (p = 0.000), and trended toward fewer chest tube days (p = 0.001) and shorter hospital length of stay (p = 0.030). The 1-, 3-, and 5-year survival rates in patients with lobectomy were 91.3, 77.7, and 64.1%, respectively, and has no significantly difference with those underwent sublobectomy (87.2, 74.4, and 61.5%, respectively, p = 0.623). Subgroups survival analysis showed no significant difference in the OS and DFS for patients with T < 2 cm or %FEV1<80%, but survival after sublobectomy was worse if performed on patients with larger tumours (T ≥ 2 cm) or relatively strong lung function (%FEV1≥80%).
Conclusion: We concluded that sublobectomy might achieve similar survival rates when compared with lobectomy in elderly stage I NSCLC patients, especially for patients with low %FEV1 and stage IA tumours less than 2 cm in diameter.
Zhang Z, Li F, Chen S, Hu B Thorac Cancer. 2024; 15(20):1553-1562.
PMID: 38812274 PMC: 11246781. DOI: 10.1111/1759-7714.15377.
Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
Wang Q, Song X, Zhao F, Chen Q, Xia W, Dong G Cancer Sci. 2023; 114(12):4607-4621.
PMID: 37770420 PMC: 10728016. DOI: 10.1111/cas.15971.
Righi I, Maiorca S, Diotti C, Bonitta G, Mendogni P, Tosi D Life (Basel). 2023; 13(4).
PMID: 37109476 PMC: 10146149. DOI: 10.3390/life13040947.
Qian J, Hao Y, Yu H, Wu L, Liu Z, Peng Q Cancers (Basel). 2023; 15(6).
PMID: 36980604 PMC: 10099732. DOI: 10.3390/cancers15061718.
Kadeetham K, Ngodngamthaweesuk M, Kantathut N, Samankatiwat P, Cherntanomwong P, Leelayana P SAGE Open Med. 2022; 10:20503121221142171.
PMID: 36568340 PMC: 9768823. DOI: 10.1177/20503121221142171.